Voyager Therapeutics(VYGR) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 Voyager Reports Third Quarter 2024 Financial and Operating Results –Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025– –Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target tau in Alzheimer's– –Continued partnership progress in Q3 2024 evidenced by new capsid license and new gene ther ...